Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [5142]

OncoAlert and ecancer - ESMO 2021 Day 5

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

OncoAlert and ecancer - ESMO 2021 Day 5 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )

Managing patients with EGFR exon 20 ins in NSCLC and EGFR TKI toxicity

Dr Danny Nguyen - City of Hope, Orange County, USA

Managing patients with EGFR exon 20 ins in NSCLC and EGFR TKI toxicity ( Dr Danny Nguyen - City of Hope, Orange County, USA )

KRYSTAL-1: Adagrasib as monotherapy or combined with cetuximab in patients with...

Dr Jared Weiss - UNC School of Medicine, Chapel Hill, USA

KRYSTAL-1: Adagrasib as monotherapy or combined with cetuximab in patients with CRC harboring a KRASG12C mutation ( Dr Jared Weiss - UNC School of Medicine, Chapel Hill, USA )

Neoadjuvant chemotherapy with CapeOx alone vs standard chemoradiotherapy (CRT)...

Dr Pei-Rong Ding - Sun Yat-sen University Cancer Center, Guangzhou, China

Neoadjuvant chemotherapy with CapeOx alone vs standard chemoradiotherapy (CRT) with Capecitabine for patients with LARC ( Dr Pei-Rong Ding - Sun Yat-sen University Cancer Center, Guangzhou, China )

Giredestrant plus palbociclib vs anastrozole plus palbociclib for post...

Dr Sara Hurvitz - UCLA Jonsson Comprehensive Cancer Center, Los Angeles, USA

Giredestrant plus palbociclib vs anastrozole plus palbociclib for post-menopausal, HER2-negative, untreated early breast cancer ( Dr Sara Hurvitz - UCLA Jonsson Comprehensive Cancer Center, Los Angeles, USA )

Novel therapies in multiple myeloma

Dr Joseph Mikhael - Translational Genomics Research Institute, Pheonix, USA

Novel therapies in multiple myeloma ( Dr Joseph Mikhael - Translational Genomics Research Institute, Pheonix, USA )

OncoAlert and ecancer - ESMO 2021 Day 4

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

OncoAlert and ecancer - ESMO 2021 Day 4 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )

Abiraterone acetate plus prednisolone added to ADT + docetaxel, gives 25%...

Prof Karim Fizazi - Institut Gustave Roussy, Villejuif, France

Abiraterone acetate plus prednisolone added to ADT + docetaxel, gives 25% reduction in risk of death compared to ADT + docetaxel alone in prostate cancer ( Prof Karim Fizazi - Institut Gustave Roussy, Villejuif, France )

Impact of cytogenetic abnormalities on treatment outcomes in patients with AL...

Dr Shaji Kumar - Mayo Clinic, Rochester, USA

Impact of cytogenetic abnormalities on treatment outcomes in patients with AL amyloidosis ( Dr Shaji Kumar - Mayo Clinic, Rochester, USA )

Impact of biomarkers on pCR and survival after T-DM1 with or without ET vs...

Prof Nadia Harbeck - University of Munich, Munich, Germany

Impact of biomarkers on pCR and survival after T-DM1 with or without ET vs trastuzumab and ET in HER2/HR positive early BC ( Prof Nadia Harbeck - University of Munich, Munich, Germany )

Immunotherapy prolongs survival in recurrent, persistent or metastatic cervical...

Prof Bradley Monk - University of Arizona College of Medicine, Phoenix, USA

Immunotherapy prolongs survival in recurrent, persistent or metastatic cervical cancer ( Prof Bradley Monk - University of Arizona College of Medicine, Phoenix, USA )

6 months trastuzumab non-inferior to 12 months for HER2 positive early breast...

Prof Helena Earl - University of Cambridge, Cambridge, United Kingdom

6 months trastuzumab non-inferior to 12 months for HER2 positive early breast cancer ( Prof Helena Earl - University of Cambridge, Cambridge, United Kingdom )

More from ecancer